Powered by 
Technavio
Vaxil Therapeutics | Data-Driven Analysis and Industry Review
Published: August 21, 2024Vaxil Therapeutics is a clinical-stage biotechnology company based in Israel, focused on developing immune-oncology therapies using its proprietary Immuno-Onco Platform. The platform is designed to enhance the immune system's ability to recognize and attack various types of cancer cells. Vaxil's lead product, Immuno-Onco Therapeutic Vaccine (IOTV), is a therapeutic cancer vaccine, which is currently undergoing clinical trials for the treatment of multiple myeloma and other solid tumors. The company's mission is to harness the power of the immune system to develop effective and safe cancer therapies, with the goal of improving patients' lives and contributing to the global fight against cancer.'
1. Focus on developing oral immunotherapies using proprietary technology platform: Vaxil Therapeutics specializes in creating oral vaccines using its unique "Mimotopes" technology, which targets specific antigens to stimulate an immune response without the need for injections.
2. Collaborations and partnerships: The company has formed strategic collaborations with leading institutions and organizations, including the National Institutes of Health (NIH), to advance its pipeline of oral immunotherapies for various indications, such as cancer and infectious diseases.
3. Preclinical and clinical stage pipeline: Vaxil Therapeutics' pipeline includes several candidates in preclinical and clinical development, targeting indications like colorectal cancer, hepatitis B, and COVID-19.
4. Strong intellectual property position: The company holds a robust intellectual property portfolio, with multiple patents and patent applications covering its Mimotopes technology and oral immunotherapies.
5. Experienced management team: Vaxil Therapeutics boasts a seasoned management team with extensive experience in drug development, clinical trials, and business strategy, positioning the company well for continued growth and success.
1. Vaxil Therapeutics is a clinical-stage biotechnology company specializing in the development of immune-oncology therapies using its proprietary Immuno-Oncology Platform, Immuno-Oncology Therapeutic Antigens (IOTA).
2. The company's Immuno-Oncology Platform is designed to identify and develop therapeutic cancer targets using a unique approach that combines bioinformatics, computational biology, and experimental validation.
3. Vaxil Therapeutics' lead product, VaxHepB, is a therapeutic cancer vaccine for the prevention and treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
4. The company's pipeline also includes VaxImmune, a therapeutic cancer vaccine for the treatment of multiple myeloma, and VaxFib, a therapeutic cancer vaccine for the treatment of fibrosis-related cancers.
5. Vaxil Therapeutics collaborates with leading academic and research institutions, as well as industry partners, to advance its pipeline and expand its technology platform.
Browse Our Research Portfolio In Vaxil Therapeutics Markets
Health Care
Pharmaceuticals
Pharmaceuticals
About Technavio
With unparalleled market insights, our research is designed to elevate your business to new heights. Technavio stands at the forefront of market research with a global perspective. Our approach is grounded in four key principles: accessible reports, comprehensive industry analysis, a focus on innovative and emerging technologies, and competitive pricing. We are dedicated to empowering companies and executives to make informed, timely, and strategic decisions.
